P53 represses pyrimidine catabolic gene dihydropyrimidine dehydrogenase (DPYD) expression in response to thymidylate synthase (TS) targeting

Nucleotide metabolism in cancer cells can influence malignant behavior and intrinsic resistance to therapy. Here we describe p53-dependent control of the rate-limiting enzyme in the pyrimidine catabolic pathway, dihydropyrimidine dehydrogenase (DPYD) and its effect on pharmacokinetics of and response to 5-fluorouracil (5-FU). Using in silico/chromatin-immunoprecipitation (ChIP) analysis we…

Read the full article here

Source: Scientific Reports

Categories: Hem/Oncs

Tweets with this article

Wafik S. El-Deiry, MD, PhD, FACP

@Aiims1742 @BldCancerDoc @SethRotz @GIcancerDoc @drallysonocean @aakonc @ShaalanBeg 5-FU is a great drug for GI cancer, cures many in adjuvant setting in CRC & even some with stage IV. But we still can’t predict who will be cured. MSI+ more resistant, DPD mutant more sensitive, p53 represses DPYD that is derepressed when p53 is mutant https://t.co/j6XTanmdFe

Sen. Hickenlooper to visit CU Anschutz Cancer Center in Aurora, discuss possible medical research funding cuts

Sen. John Hickenlooper will tour the CU Anschutz Cancer Lab in Aurora and discuss the impacts of the Trump administration’s decision to cut billions of…

Wafik S. El-Deiry, MD, PhD, FACP March 19, 2025

Mass General Brigham will spend $400 million on cancer care in wake of layoffs

Mass General Brigham said it will invest $400 million on cancer care, not long after announcing layoffs.

Wafik S. El-Deiry, MD, PhD, FACP March 19, 2025

WIN Consortium revolutionizing precision oncology for cancer patients

A new precision oncology paper was published in Oncotarget, Volume 16, on March 12, 2025, titled “Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine:…

Wafik S. El-Deiry, MD, PhD, FACP March 19, 2025

Mass General Brigham to invest $400 million to open new cancer institute before Dana-Farber partnership ends – The Boston Globe

The renovations at the state’s biggest health system will help create the Mass General Brigham Cancer Institute.

Wafik S. El-Deiry, MD, PhD, FACP March 19, 2025

Prevention and screening drive drop in cancer deaths

Most deaths avoided from common cancers between 1975 and 2020 could be traced to prevention and screening efforts.

Wafik S. El-Deiry, MD, PhD, FACP March 18, 2025

Books that mattered to me this year – The Cancer Letter

Over the past year, I noticed several books written by giants in our field, people everyone knows, people I am honored to know personally. I…

Wafik S. El-Deiry, MD, PhD, FACP March 18, 2025

Why Don’t U.S. Guidelines Recommend DPYD Testing Before Chemotherapy?

If a person carries a mutation in the DPYD gene, certain chemotherapies, including fluorouracil (5-FU) or capecitabine (Xeloda or CAPE), may make them ill or…

Wafik S. El-Deiry, MD, PhD, FACP March 18, 2025

Low-dose irradiation of the gut improves the efficacy of PD-L1 blockade in metastatic cancer patients

Chen et al. propose a mechanism accounting for the abscopal effects of radiotherapy on distal non-irradiated cancer lesions under immunotherapy. In eight retrospective studies and a…

Wafik S. El-Deiry, MD, PhD, FACP March 17, 2025

Governor promises investment for University of Missouri’s cancer treatment development

As federal and state governments look for ways to save money, there is one project Missouri sees fit for extra investments: cancer treatments.

Wafik S. El-Deiry, MD, PhD, FACP March 17, 2025

Remembering R. Scott Hawley, Ph.D.

A Legacy of Scientific Excellence and Mentorship

Wafik S. El-Deiry, MD, PhD, FACP March 17, 2025

Related Articles